Biopharma Predicts ‘Significant’ R&D Reductions With Medicare IPI Model

Manufacturers refute Administration claims that Medicare International Pricing Index model will have minimal impact on industry innovation.

PCR strip test tubes and micropipette in genetics laboratory. Toned photo

Most big prescription drug manufacturers anticipate the proposed Medicare International Pricing Index (IPI) model for lowering Part B drug prices would have a substantial, negative effect on research and development in the industry, according to the Pharmaceutical Research and Manufacturers of America.

Seventy-seven percent of PhRMA members responding to a recent internal survey said that if the IPI were to go into...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access